Jennifer Kuretski
Family · Jupiter, FLNPI 1184950404
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Gilead at 59.9% of the total. 2025 is the largest year on record at $28,421, 9.3 times the $3,071 reported in 2021. Among family clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 562 payments — averaging $102.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$35K
- Viiv Healthcare Company$19K
- Merck$971
- Johnson & Johnson$838
- Janssen Products, LP$618
- Theratechnologies Inc.$266
- plus $1K from 16 others
Across 5 payments — averaging $24,523 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$66K
- Viiv Healthcare Company$57K
What the payments were for
- Consulting fees$2,7505%
- Speaking & faculty fees$33,35858%
- Travel & lodging$5,49210%
- Food & beverage$15,80627%
- Education$2130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 233 | $34,505 |
| Viiv Healthcare Company | 186 | $19,281 |
| Merck | 40 | $971 |
| Johnson & Johnson(2 entities) | 53 | $838 |
| Janssen Products, LP | 6 | $618 |
| Theratechnologies Inc. | 12 | $266 |
| Insmed, Inc. | 3 | $206 |
| Novo Nordisk | 4 | $177 |
| EMD Serono, Inc. | 3 | $157 |
| Biohaven Pharmaceuticals, Inc. | 2 | $116 |
| AbbVie | 4 | $94 |
| Janssen Scientific Affairs, LLC | 2 | $90 |
| Napo Pharmaceuticals Inc | 3 | $69 |
| Lundbeck LLC | 2 | $45 |
| AstraZeneca | 1 | $44 |
| Lilly USA, LLC | 2 | $43 |
| Paratek Pharmaceuticals, Inc. | 1 | $23 |
| Dynasplint Systems Inc. | 1 | $19 |
| GSK | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Amgen | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$57,619 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 194 | $830,868 |
| DescovyEmtricitabine/Tenofov Alafenam | 95 | $234,866 |
| CabenuvaCabotegravir/Rilpivirine | 31 | $196,063 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 38 | $180,703 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 34 | $130,501 |
| DovatoDolutegravir Sodium/Lamivudine | 29 | $84,596 |
| ApretudeCabotegravir | 21 | $79,980 |
| PrezcobixDarunavir/Cobicistat | 32 | $77,310 |
| JulucaDolutegravir/Rilpivirine | 20 | $67,769 |
| TivicayDolutegravir Sodium | 18 | $66,666 |
| IsentressRaltegravir Potassium | 13 | $25,539 |
| PifeltroDoravirine | 12 | $20,788 |
| TrulicityDulaglutide | 12 | $11,542 |
| ValacyclovirValacyclovir Hcl | 38 | $1,651 |
| Lisinopril | 12 | $89 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $34,505 | $1,196,236323 claims |
| Viiv Healthcare CompanyCabenuva, Dovato, Apretude, Juluca, Tivicay | $19,281 | $495,073119 claims |
| Janssen Products, LPSymtuza | $618 | $180,70338 claims |
| Johnson & JohnsonPrezcobix | $838 | $77,31032 claims |
| MerckIsentress, Pifeltro | $971 | $46,32725 claims |
| Lilly USA, LLCTrulicity | $43 | $11,54212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.
Other family in Jupiter
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
- Deena RodneyMaitland$323K
- Yamila MelendezMiami$212K
- Holly BoydLand O Lakes$200K
- Rachael BuschLoxahatchee$189K
- Victor Tatis de la NuezMiramar$161K
- Ronda CrewsJax Bch$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.